Long-acting hormonal contraceptive methods for women

Catherine d'Arcangues, Ph.D., M.D. Department of Reproductive Health and Research World Health Organization Training in Reproductive Health Research Geneva, 21 March 2006



Reproductive Health and Research



Rationale for the development of long-acting methods of contraception


- Methods that do not require daily use or interfere with sexual intercourse
 [Duration of action: 7 days → 7 years]
 meter use-effectiveness
- Methods with improved pharmacokinetic profile
 reduced side-effects
- Note: dependence on health care provider



Reproductive Health and Research



Schematic representation of expected PK profiles of progestogens administered by different routes and in different formulations





Reproductive Health and Research



Long-acting methods

- Injectables
- Implants
- Vaginal rings
- Transdermal systems







Injectable contraceptive preparations

• Two-to-three monthly: progestogen-only

Once-a-month: progestogen-estrogen combinations



SHR Reproductive Health and Research



Two-to-three monthly injectables

Depot-medroxyprogesterone acetate (DMPA)
 Norethisterone enanthate (NET-EN)
 Mechanism of action:

 ovulation inhibition
 additional effects on endometrium, tubal function and cervical mucus



SHR Reproductive Health and Research



Rationale for the development of combined injectable contraceptives

Offer to women an alternative to progestogenonly injectable contraceptives, which ensures:


- a more regular vaginal bleeding pattern:
 - by adding an estrogen
- faster return to baseline fertility upon discontinuation:
 - through improved pharmacokinetic profile







Idealized pharmacokinetic/pharmacodynamic profile of a typical combined monthly injectable contraceptive





Reproductive Health and Research

ЯR



Once-a-month combined injectable contraceptives Main preparations currently available

Trade name

Perlutal Topasel

Cyclofem Lunelle

Mesigyna Norigynon Chinese injectable No1

Mego-E

World Health Organization

Composition

Dihydroxyprogesterone acetophenide 150 mg + E₂ enanthate 10 mg

DMPA 25 mg + E₂ cypionate 5 mg

NET-EN 50 mg + E₂ valerate 5 mg

 17α -hydroxyprogesterone caproate 250 mg + E₂ valerate 5 mg

Megestrol acetate 25 mg + $17\beta E_2 3.5 mg$

Availability

Latin America, Spain

22 c., Latin America, Indonesia, Thailand

Latin America, Turkey, 7 African c., China

China

China



UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

Reproductive Health and Research

Percentage of ovulatory cycles after administration of various monthly injectables

Formulation	Dose (mg)	3 rd treatment month	1 st follow-up month	2 nd follow-up month
DMPA	25	0	24	48
DMPA E ₂ Cyp	25 5	0	60	71
DMPA E ₂ Cyp	12.5 2.5	0	60	90
DMPA E ₂ Cyp	12.5 5	42	100	100



Reproductive Health and Research

ЯR

(Qiarp

WHO phase III clinical trials of Cyclofem, Mesigyna and DMPA. Cumulative life table discontinuation rates per 100 women at 12 months

Event	Cyclofem	Mesigyna	DMPA
Pregnancy	0	0.2	0
Bleeding-related reaso	ns 6.3	7.5	15.5
Amenorrhoea	2.1	1.6	12.5
Other medical reasons	6.3	6.6	4.3
Non-medical reasons	15.1	16.6	10.1
Lost to follow up	11.4	10.5	8.6
Total discontinuations	35.5	36.8	41.2
Woman-months	10 969	10 608	5 429
		Erom	



FR Reproductive Health and Research From : WHO, 1986,1988



Proportions (%) of women experiencing different types of bleeding patterns. Months 6-9 of a one year diary

Group	(n)	Ameno- rrhoea	Infrequent bleeding	Frequent bleeding	Irregular bleeding	Prolonged bleeding	Regular pattern	
Untreated	3 893	1.3	2.8	0.1	5.4	9.9	90.1	
Cyclofem	802	1.1	5.4	2.8	25.4	9.4	61.3	
Mesigy na	766	1.3	2.9	4.9	24.8	12.6	63.3	
DMPA	311	37.0	24.8	8.3	27.7	17.3	6.4	

From: Fraser, 1994; Sang et al, 1995; Coutinho et al, 1997



SHR Reproductive Health and Research



Mechanisms of progestin-induced endometrial bleeding

- Abnormal angiogenesis → neovascular formations, increased microvascular density, reduced smooth muscle α-actin, deficient microvascular basement membrane, dilated surface vessels.
- Infiltration, proliferation and activation of leukocytes and mast cells → expression and activation of growth factors, cytokines and proteases (MMPs), degradation of extracellular matrix.
- Abnormal epithelium with reduced cytokeratin formation or deposition \rightarrow less likely to contain micro-hemorrhages.







12-months life-table d/c rates for medical reasons in multicentre trials of DMPA, NET-EN and Cyclofem

	DMPA	NET-EN	Cyclofem
Abdominal discomfort	1.1	0.6	0.1
Weight gain	2.1	1.6	1.5
Anxiety/depression	0.7	0.9	0.3
Fatigue	0.9	0.9	0.4
Dizziness	1.2	1.6	1.2
Headaches	2.3	2.0	1.2
Decreased libido	0.9	0.6	-
Hypertension	0.5	0.7	0.8
TOTAL	8.7	9.3	6.3
Woman-months	20,550	10,361	10,969



Reproductive Health and Research



Metabolic effects of DMPA and NET-EN

- Small degree of insulin resistance
- Moderate unfavourable lipid changes.
 In epidemiological studies: no increased risk of stroke, VTE or AMI in healthy women BUT increased risk of stroke in those with hypertension
- No quantitative effect on milk production, some changes in milk composition
- No measurable effect on breast-fed infants (growth, hypothalamic-pituitary gonadal axis)
 - **Delayed return of fertility after use discontinuation**







Metabolic effects of Cyclofem and Mesigyna

- Minor lipid changes, which revert promptly at discontinuation
- Minor hemostatic changes, which revert promptly at discontinuation
- No significant change in glucose metabolism
- No studies on their effect on lactation
- Delay in the return to fertility during 3 months after d/c







Return of ovulation and fertility after prolonged use of different methods

n	Median time to	Cumulative
	conception (months)	conception rate at one year (%)
70	5.5	82.9
796	5.5	76.2
125	4.5	75.8
437	3.0	84.9
	796 125	conception (months)705.57965.51254.5



FR Reproductive Health and Research



DMPA use and risk of STIs

- 5 cross-sectional studies and 3 prospective studies
- No increased risk of infection with gonorrhoea, trichomoniasis, syphilis, herpes or HPV.
- Two studies found an increased risk of chlamydial infection with DMPA use (hazard ratios of 4.3 and 1.6, respectively) but this could be due to differential STI exposure among the study groups.



SHR Reproductive Health and Research



DMPA use and HIV acquisition

- 4 cohort studies and 14 cross-sectional studies give inconsistent results:
 - 15 find no association
 - 3 find a positive association



Reproductive Health and Research



DMPA used by HIV+ women

- No evidence that DMPA use affects HIV disease progression (one study)
- Three studies gave inconsistent results re. a possible association between DMPA use and HIV and HSV shedding
- Few data on possible interaction between DMPA and anti-retroviral drugs







Pharmacokinetic COC-ARV drug interactions

ARV	Contraceptive steroid levels	ARV levels			
Protease inhibitors					
Nelfinavir	+	No data			
Ritonavir	+	No data			
Lopinavir/ritonavir	+	No data			
Atazanavir	↑	No data			
Amprenavir	↑	+			
Indinavir	↑	No data			
Saquinavir	No data	No change			
Non-nucleoside reverse transcriptase inhibitors					
Nevirapine	+	No change			
Efavirenz	↑	No change			
Delavirdine	?↑	No data			
	ЯR	e hrp			

Reproductive Health and Research

DMPA and bone metabolism

- Between the ages of 25 and 45, slight acceleration of bone metabolism with bone resorption that is not fully compensated by bone formation, reversible upon discontinuation and without any apparent long-term effect.
- In adolescents, slow down of the normal bone mass accumulation. Current research focuses on the impact on adult bone mass and long-term risks.


Few data on the peri-menopause.



Reproductive Health and Research



Changes in bone mineral density among 182 DMPA users and 258 non-users, 18-39 years old



Source: Scholes et al, 2002



SHR Reproductive Health and Research





• First registered for this indication in 1967

- Currently registered in over 70 countries, including 10 EC countries and the USA
- Currently used by over 10 million women worldwide

Approved by the US Food and Drug Administration (USFDA) in 1982



Reproductive Health and Research



Relative risks of 5 neoplasms in women who have ever used DMPA WHO Collaborative Study

	_	of Subjects		Relative Risk
Cancer Site	Cases	Controls*	(9	95% CI)
Endometrium	122	939	0.21	(0.06-0.79)
Ovary	224	1,781	1.07	(0.6-1.8)
Liver	57	290	1.0	(0.4-2.8)
Breast	869	11,890	1.21	(0.96-1.52)
Cervix	2,009	9,583	1.1	(0.96-1.29)

* Controls matched with cases by age, centre and year of entry into study



ЯR

Reproductive Health and Research



DMPA and Breast Cancer (1)

Setting: New Zealand (entire country) Thailand (3 centres) Kenya (1 centre) Mexico (1 centre)

1,768 cases and 13,905 controls

DMPA used by 14.1% cases and 14.2% controls



World Health Organization

SHR Reproductive Health and Research



DMPA and Breast Cancer (2)

RR (95% CI) in ever users of DMPA = 1.1 (0.97 - 1.4)

Risk increased during first 4 years after initial exposure, in women < 35 years at diagnosis; small n

Risk did not increase with duration of use and was not increased in women who began use > 5 years previously

Maximum increase in risk attributable to DMPA:

3.2 - 4.5 cases per 100 000 women-years







DMPA and Invasive Squamous Cell Cervical Cancer WHO Collaborative Study

Months	Number of	Subjects	Relative Risk
of use	Cases	Controls	(95% CI)
0	782	5,184	1.0
1-12	58	216	1.4 (1.0 - 2.0)
13-24	50	92	1.2 (0.7 – 2.0)
25-60	17	127	0.6 (0.4 – 1.1)
> 60	26	86	1.4 (0.9 – 2.2)
Ó	Ян		e hrp

UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

World Health Organization

Reproductive Health and Research

DMPA and Cervical Carcinoma in situ (1)

Setting: Mexico, Thailand 1,217 cases and 8,956 controls

23.3% cases and 15.4% controls had ever used DMPA

RR (CI 95%) = 1.43 (1.22 - 1.67) adjusted for age, number of pregnancies, use of OC, Pap smear frequency



SHR Reproductive Health and Research



DMPA and Cervical Carcinoma in situ (2)

The risk increased with duration of use but decreased with time since first and last use.

Since no relationship was established between invasive cervical cancer and DMPA in this same study, the findings suggest that if DMPA increases the risk of cervical CA *in situ*:

- this is a reversible effect, or
- cervical lesions induced by DMPA do not progress to invasive disease







Implantable contraceptives







Implantable contraceptives for women

Progestin	Tradename	Units	Duration of action
Levonorgestro	el Norplant*	Six capsules	7 y
Levonorgestro	el Jadelle*	Two rods	5 y
Etonogestrel	Implanon	Single rod	3 y

*Sino-implants Domestic No. I and II not shown are generic versions of Norplant and Jadelle respectively, available in China. From: Croxatto 2001




SHR Reproductive Health and Research



Norplant

Jadelle




From: Croxatto 2001



SHR Reproductive Health and Research



Serum level of levonorgestrel in women using Norplant for 8 years






Reproductive Health and Research

ЯR

From: Diaz et al 1987



Serum levels of levonorgestrel in women using Norplant or Jadelle



Norplant and Jadelle

 Mechanism of action: mostly ovulation inhibition luteal phase abnormalities cervical mucus thickening
 Efficacy: 5 year cumulative pregnancy rate: 1.1 per 100

- highest rates in women < 25 y/o or > 70 kg
- For Norplant.
- 7 year cumulative pregnancy rate: 1.9 per 100







Cumulative gross pregnancy rates per 100 Norplant^R users through 5 years

Weight	Rate	SE	
< 50 kg	0.2	0.2	
50-59 kg	3.4	0.9	
60-69 kg	5.0	1.4	
> 70 kg	8.5	2.3	

From Population Council, 1990

World Health Organization

Reproductive Health and Research



Discontinuation resulting from adverse experiences: Gross annual rate per 100 Norplant^R users

Year				
1	2	3	4	5
0.1	7.0	4.0	2 2	2.0
9.1	7.9	4.9	3.3	2.9
6.0	5.6	4.1	4.0	5.1
15.1	13.5	9.0	7.3	8.0
19.0	22.6	20.8	23.3	22.4
	9.1 6.0 15.1	9.1 7.9 6.0 5.6 15.1 13.5	1 2 3 9.1 7.9 4.9 6.0 5.6 4.1 15.1 13.5 9.0	12349.17.94.93.36.05.64.14.015.113.59.07.3

From Sivin, 1990



SHR Reproductive Health and Research



Bleeding patterns (%) of Norplant^R users during 5 years of use, assigned to most frequent category for each year

		Year				
		1	2	3	4	5
1						
1	Regular	26.6	54.7	53.5	66.8	62.5
	Irregular	66.3	40.0	39.9	28.1	37.5
	Amenorrhea	7.1	5.3	6.6	5.1	0
	Women-years No. of women	198.0 215	127.9 138	101.9 115	68.8 77	34.9 46
				Adapted from	n Shoupe et	al., 1991
		ЯR			trp	

Reproductive Health and Research

UNDP • UNFPA • WHO • World Bank Special Programme of Research, Development and Research Training in Human Reproduction

World Health Organization

Adverse effects with Norplant use (other than menstrual disorders)

Symptom	% users
Headache	10 - 30
Weight gain	4 - 22
Acne	3 - 22
Hair loss / hirsutism	2 - 5
Dizziness	4 - 11
Mood changes	1 - 9



SHR Reproductive Health and Research



Implanon

- EVA rod releasing etonogestrel
- More consistent ovulation inhibition
- No pregnancies observed in 5629 years of exposure (women > 70kg were excluded)
- Vaginal bleeding patterns:
 - 30-40% amenorrhea throughout 3 years
 - 30% infrequent bleeding
 - 10-20% prolonged bleeding





Metabolic effects of implants (Norplant, Jadelle, Implanon)

- Lipid effects: small or none.
- Carbohydrate metabolism: mild insulin resistance in some users
- Clotting and fibrinolytic systems: minor changes
- Liver function: elevated bilirubin in some women, within normal range
 - Note: Predictive value questionable No studies in women at risk





Reproductive Health and Research



Safety of Norplant (1)

Potential beneficial effects: decreased risk of ectopic pregnancy decreased risk of pelvic inflammatory disease and lower genital tract infection No effect on: bone density anaemia ovarian cyst enlargement recovery of fertility connective tissue disorders



Я

Reproductive Health and Research



Safety of Norplant (2)

 Potential adverse effects that need further evaluation:

increased risk of hypertension increased risk of gallbladder disease hormonal side-effects No studies large enough to assess effect on: cardio-vascular disease cancer **HIV/AIDS** diabetes



SHR Reproductive Health and Research



Contraceptive implants and lactation

- Breast-feeding women using Norplant:
 - experience longer periods of amenorrhea
 - after weaning, bleeding pattern same as in nonnursing users
 - no effect on bone metabolism
- Infants breast-fed by women using Norplant or Implanon:
 - absorb about 100 ng/day of progestogen
 - no effect on infant growth and development
 - with Norplant: slight 1 in mild respiratory diseases, eye infections and skin conditions during the first year (?)





Percentage of women with insertion site complications during the first year of Norplant use

2674 women in 19 centres in 7 countries

	% All Centres	% Range Individual Centres
INFECTION	0.8	0 – 3.0
EXPLUSION	0.4	0 – 3.0
LOCAL REACTION	4.7	0 – 18.0
- Pain	2.2	
- Itching	1.9	
- Rashing	g 0.3	
- Other	0.3	
		From: Klavon and Grubb, 1990




SHR Reproductive Health and Research



Occurences of Insertion Site Infection and Implant Expulsion, by Follow-up Interval

Infection <a>D Expulsion



* Follow-up interval and the inclusive days post-insertion were: 1-month (days 1-60), 3-month days (61-136), 6-month (days 137-273), and 12-month (days 274-456).



Reproductive Health and Research



From: Klavon and Grubb. 1990

Lessons learnt from Norplant as a delivery system

Positive attributes

- long duration of action; no action required from user for 5 y.
- near-zero order release of minimal dose required: minimal metabolic changes, good reversibility but reduced efficacy in heavier women
- Specific requirements
- provider training for careful insertion and removal, and for careful counselling
- adaptation of health services; planning of removals







Lessons learnt from Norplant as a delivery system

Controversies

- coercive use by providers/target-driven national family planning programmes
 - financing, including free insertion and payment for early removal
- misuse by judiciary system and politicians
 - class action suits in the USA and the UK



Reproductive Health and Research



Contraceptive vaginal rings







Contraceptive vaginal rings





FR Reproductive Health and Research



CONTRACEPTIVE VAGINAL RINGS

- releasing estrogen
 + progestogen
 (3 weeks in/1 week out)
 NUVARING
- releasing progesterone (continuous use over 3 months)
 PROGERING






Reproductive Health and Research



NUVARING

(120 μg/day etonogestrel + 15 μg/day EE) Serum concentration-time curves






Reproductive Health and Research

ЯR



NUVARING

Maximum estradiol concentration and follicular diameter during normal and extended use





Reproductive Health and Research

ЯR



NUVARING - Phase III clinical trials

- Pearl index of 0.77 (CI: 0.37-1.41) with perfect use,
 - 1.18 with actual use in clinical trial setting
- Withdrawal bleeding when expected (2-4 days after ring removal) in 98.5 % cycles, lasting 4-5 days.
- Breakthrough bleeding/spotting in 5.5 % of all cycles.
- Complaints of hormonal side-effects: 3-6 %
- Device-related events (foreign body sensation, coital pb, expulsion): 4.4 %
- No adverse effect on cervical or vaginal cytology during one year of use.
- Minimal effects on lipid, CHO and hemostatic variables.







PROGERING

(15 \rightarrow 5 mg/day progesterone, over 3 months) Pre-registration study

- 285 ring users vs 262 CuT380A IUD users, all nursing women
- one year follow-up: no pregnancy in either group
 - breast-feeding and infant growth similar in both groups
- mean duration or amenorrhea: 12 months in ring users vs 6 months in IUD users
- some early discontinuations among ring users because of discomfort or ring expulsion





Transdermal systems



Reproductive Health and Research



Transdermal systems ORTHO-EVRA




- 20 cm² (4.5 cm side), three-layered patch:
 - outer polyethelene+polyester protective layer
 - middle layer that contains an adhesive and the two contraceptive steroids
 - inner, clear polyester liner, peeled off before use
- releasing 150 μg/day norelgestromin (active metabolite of norgestimate)+ 20 μg/day EE
- blood levels reach steady state in < 48 hours and are maintained over 7 days (+2 days as safety window)







Mean norelgestromin serum levels (ng/ml) following application of EVRA for 7 and 10 days



Time (days)



ЯR

Reproductive Health and Research



ORTHO-EVRA

- Same mechanism of action as the combined OC.
- Differences with OC in randomized clinical trials:
 - better compliance (88% vs 77%)
 - application site reaction in 20% users (2.6% d/c for this reason)
 - patch partial or complete detachment needing replacement patch: 5%
 - breast discomfort (19% vs 6%). 1% d/c for this reason.
 - dysmenorrhea (14% vs 10%)



SHR Reproductive Health and Research

